secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096191
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6
--------------------------------------------------------------------------------

- Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.
- Cash, cash equivalents and marketable securities of $97.5M as of June 30, 2024; runway through mid-2026.
- BDC-3042 Phase 1 advanced to Cohort 6; no dose-limiting toxicities in Cohort 5.
- BDC-4182 (claudin 18.2-targeting ISAC) abstract accepted at SITC 2024; IND-enabling activities ongoing.
- Collaboration revenue $1.3M; R&D expenses $15.4M; G&A expenses $4.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/0000950170-24-096191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/bolt-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer